Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa
Table 3
Changes of inflammatory cytokines in inflamed mucosa of CD patients before and 10 weeks after IFX treatment.
Remission group ( = 25)
Response group ( = 15)
Failure group ( = 13)
IFN-
Week 0
112.6 34.5
118.9 32.1
117.2 30.4
Week 10
32.5 11.2*
64.7 21.6*
109.2 32.6
TNF
Week 0
62.3 12.5
63.8 13.2
61.8 15.8
Week 10
11.5 4.5*
40.1 8.9+
58.9 14.7
IL-10
Week 0
8.5 3.6
9.8 3.9
9.2 3.5
Week 10
12.8 2.9
12.5 4.1
8.9 3.0
IL-17A
Week 0
35.8 10.5
34.6 9.8
36.5 8.7
Week 10
7.6 3.2*
18.8 5.2*
36.7 10.1
IL-21
Week 0
21.3 6.3
20.1 7.2
21.4 6.1
Week 10
3.6 1.2*
11.9 3.5*
19.8 5.9
IL-23p19
Week 0
24.5 ± 6.8
25.5 5.4
26.9 5.7
Week 10
5.8 2.1*
12.8 4.3+
24.5 6.6
IL-25
Week 0
8.2 3.2
9.8 3.6
7.9 3.5
Week 10
26.9 8.3*
15.6 4.8
8.8 2.9
RORC
Week 0
26.1 7.0
29.4 8.8
25.8 7.3
Week 10
7.6 3.5*
16.7 6.7*
23.4 5.7
< 0.005; +P < 0.05 versus values before initial therapy with IFX.
